The Coronavirus Vaccine of AstraZeneca is getting embroiled in controversy. Cases of blood clotting (blood clotting) were reported after the introduction of this vaccine in many countries of Europe. At the same time, now the company has been accused that it has used old information in the vaccine test conducted in America. US health officials gave information about it on Tuesday.
A day earlier, AstraZeneca Pharmaceutical Company said that its vaccine has been up to 79% effective in tests conducted in America. This vaccine has been prepared jointly by AstraZeneca Pharmaceutical Company and Oxford University. At the same time, the Data and Safety Monitoring Board said in a statement that it is worrying that AstraZeneca has provided incomplete data regarding the efficacy of the vaccine.
AstraZeneca’s image was clear with American results
AstraZeneca said on Monday that its COVID-19 vaccine is effective for adults of all ages. It said that its results have been revealed in the results of tests conducted in the US. After these results, it seems that after the cases of blood clotting, the way AstraZeneca’s image has been tarnished worldwide. She can be clean once again. The results of the vaccine came in the way of getting approval for this vaccine in America.
Testing was done on 30 thousand volunteers
The company said that 30,000 volunteers had participated for the test. The vaccine was up to 79 percent effective in protecting against symptoms of COVID-19. The effect of this vaccine was seen on the elderly as well. Volunteers who received the vaccine did not see any serious illness. Nor did he need to be hospitalized. These results were in line with the results made in Britain and other countries. In which it was said that the vaccine is fully capable of fighting the corona.
Company claims – Blood clot case not shown in the test
AstraZeneca also said that the independent safety monitoring organization of the study did not see serious side effects of this vaccine. In Europe, the way many countries claimed to have a blood clot after vaccination. It was not found here. Significantly, after the case of blood clot, countries like Germany, Italy, Spain had banned the use of the vaccine in Europe. However, later the European Medical Agency gave the green signal to the vaccine, after which the vaccination started again.
The application is intended for use in the US by the vaccine
In the coming week, AstraZeneca has to apply for vaccine approval before the American Food and Drug Administration. After this, the advisors of the government will discuss whether it will be approved in the country or not. Use of the vaccine in the US is permitted by the Food and Drug Administration and the Centres for Disease and Prevention. But before this, independent advisory committees do a thorough review of the vaccine’s data.